1) Farrand KF, Fridman M, Stillman IO, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol 2017;182:90-8.
2) Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008;14(3 Suppl):S102-6.
3) Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf 2017;15:438-510.
6) Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf 2017;15:575-628.
7) Halterman JA, Kwon HM, Wamhoff BR. Tonicity-independent regulation of the osmosensitive transcription factor TonEBP (NFAT5). Am J Physiol Cell Physiol 2012;302:C1-8.
8) Sawazaki R, Ishihara T, Usui S, et al. Diclofenac protects cultured human corneal epithelial cells against hyperosmolarity and ameliorates corneal surface damage in a rat model of dry eye. Invest Ophthalmol Vis Sci 2014;55:2547-56.
9) Lee N, Kim D, Kim WU. Role of NFAT5 in the immune system and pathogenesis of autoimmune diseases. Front Immunol 2019;19:270.
10) Zhou P, Xie W, Luo Y, et al. Protective effect of total saponins of Aralia elata (Miq.) on endothelial cell injury induced by TNF-α, via modulation of the PI3/Akt and NF-κB signaling pathways. Int J Mol Sci 2018;21:36.
11) Kim SJ, Yoo WS, Kim H, et al. Aralia elata prevents neuronal death by downregulating tonicity response element binding protein in diabetic retinopathy. Ophthalmol Res 2015;54:82-95.
13) Chung YS, Choi YH, Lee SJ, et al. Water extract of Aralia elata prevents cataractogenesis in vitro and in vivo. J Ethnopharmacol 2005;101:49-54.
14) Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf 2017;15:276-83.
16) Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010;51:6125-30.
17) Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011 151:792-8. e1.
18) Begley CG, Himebaugh N, Renner D, et al. Tear breakup dynamics: a technique for quantifying tear instability. Optom Vis Sci 2006;83:15-21.
21) Zivandeh N, Yildiz E, Özer B, et al. Androgen suppresses hyperosmolarity-induced inflammatory mediators in human corneal epithelial cells. Cornea 2020;39:886-91.
23) Woo SK, Nahm O, Kwon HM. How salt regulates genes: function of a Rel-like transcription factor TonEBP. Biochem Biophys Res Commun 2000;278:269-71.
25) Choi SY, Lee-Kwon W, Kwon HM. The evolving role of TonEBP as an immunometabolic stress protein. Nat Rev Nephrol 2020;16:352-64.
26) Lee JH, Suh JH, Choi SY, et al. Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis. Gut 2019;68:347-58.
27) Roth I, Leroy V, Kwon HM, et al. Osmoprotective transcription factor NFAT5/TonEBP modulates nuclear factor-kappaB activity. Mol Biol Cell 2010;21:3459-74.
28) Kim YS, Kim M, Choi MY, et al. Aralia elata (Miq) seem extract decreases O-GlcNAc transferase expression and retinal cell death in diabetic mice. J Med Food 2017;20:989-1001.